Schrodinger is trading 5.3% lower at $25.83 on October 12, 2026, with no clear company-specific catalyst identified. - A Bristol Myers Squibb collaboration story refers to an agreement announced August 5, not a new October 12 announcement. - The broader market was mixed, not sharply lower, and does not clearly explain the decline. - Recent sessions were volatile, but attributing the move to profit-taking or another specific cause would be speculative.